NSAID developer Iroko Pharmaceuticals withdraws IPO

Comment

Shutterstock photo

Iroko Pharmaceuticals, which is developing high-efficacy, low-dose NSAID therapeutics, withdrew its plans for an initial public offering on Wednesday citing poor market conditions. The Philadelphia, PA-based company was founded in 2007 and booked $10 million in sales for the 12 months ended March 31, 2013. Iroko Pharmaceuticals initially filed confidentially on March 1, 2013. Jefferies & Co., William Blair and Canaccord Genuity were set to be the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com